# BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

> **NCT01389323** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 448 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Peg-Interferon Alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01389323
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-09
- **Final completion:** 2014-01
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389323, "BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01389323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*